Current concept of reverse cholesterol transport and novel strategy for atheroprotection

Journal of Cardiology

Volumn 60, Issue 5, 2012, Pages 339-343

  Ono, Koh ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Coronary heart disease; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; MicroRNA; Statin

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEART PROTECTION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MACROPHAGE; NONHUMAN; PATIENT COMPLIANCE; REVIEW; RISK REDUCTION;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES; MICRORNAS; MOLECULAR TARGETED THERAPY;

EID: 84868629989     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.07.014     Document Type: Review

References (52)

1. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
2. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., Armitage J., Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
3. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
4. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., Kastelein J.J., Bittner V., Fruchart J.C. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
5. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R., Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
6. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., Lopez-Sendon J., Mosca L., Tardif J.C., Waters D.D., Shear C.L., Revkin J.H., Buhr K.A., Fisher M.R., Tall A.R., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
7. Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., Koprowicz K., McBride R., Teo K., Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
8. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., Byun J., Vuletic S., Kassim S., Singh P., Chea H., Knopp R.H., Brunzell J., Geary R., Chait A., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
9. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D.M., Chroni A., Yonekawa K., Stein S., Schaefer N., Mueller M., Akhmedov A., Daniil G., Manes C., Templin C., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011, 121:2693-2708.
10. Tamehiro N., Shigemoto-Mogami Y., Kakeya T., Okuhira K., Suzuki K., Sato R., Nagao T., Nishimaki-Mogami T. Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem 2007, 282:21090-21099.
11. Maejima T., Yamazaki H., Aoki T., Tamaki T., Sato F., Kitahara M., Saito Y. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004, 324:835-839.
12. Berge K.G., Canner P.L. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991, 40(Suppl. 1):S49-S51.
13. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000, 2:36-46.
14. Guyton J.R., Bays H.E. Safety considerations with niacin therapy. Am J Cardiol 2007, 99:22C-31C.
15. Glomset J.A., Wright J.L. Some properties of a cholesterol esterifying enzyme in human plasma. Biochim Biophys Acta 1964, 89:266-276.
16. Glomset J.A. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 1968, 9:155-167.
17. Wang M.D., Franklin V., Marcel Y.L. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler Thromb Vasc Biol 2007, 27:1837-1842.
18. Wang X., Collins H.L., Ranalletta M., Fuki I.V., Billheimer J.T., Rothblat G.H., Tall A.R., Rader D.J. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007, 117:2216-2224.
19. Zanotti I., Pedrelli M., Poti F., Stomeo G., Gomaraschi M., Calabresi L., Bernini F. Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 2011, 31:74-80.
20. Larrede S., Quinn C.M., Jessup W., Frisdal E., Olivier M., Hsieh V., Kim M.J., Van Eck M., Couvert P., Carrie A., Giral P., Chapman M.J., Guerin M., Le Goff W. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol 2009, 29:1930-1936.
21. Zhang Y., Zanotti I., Reilly M.P., Glick J.M., Rothblat G.H., Rader D.J. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003, 108:661-663.
22. Alexander E.T., Weibel G.L., Joshi M.R., Vedhachalam C., de la Llera-Moya M., Rothblat G.H., Phillips M.C., Rader D.J. Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Arterioscler Thromb Vasc Biol 2009, 29:1496-1501.
23. Navab M., Anantharamaiah G.M., Reddy S.T., Hama S., Hough G., Grijalva V.R., Wagner A.C., Frank J.S., Datta G., Garber D., Fogelman A.M. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004, 109:3215-3220.
24. Amar M.J., D'Souza W., Turner S., Demosky S., Sviridov D., Stonik J., Luchoomun J., Voogt J., Hellerstein M., Remaley A.T. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther 2010, 334:634-641.
25. Bielicki J.K., Zhang H., Cortez Y., Zheng Y., Narayanaswami V., Patel A., Johansson J., Azhar S. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 2010, 51:1496-1503.
26. Rader D.J., Ikewaki K., Duverger N., Schmidt H., Pritchard H., Frohlich J., Clerc M., Dumon M.F., Fairwell T., Zech L., Santamarina-Fojo S., Brewer H.B. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 1994, 93:321-330.
27. Alexander E.T., Vedhachalam C., Sankaranarayanan S., de la Llera-Moya M., Rothblat G.H., Rader D.J., Phillips M.C. Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol 2011, 31:320-327.
28. Jin W., Wang X., Millar J.S., Quertermous T., Rothblat G.H., Glick J.M., Rader D.J. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab 2007, 6:129-136.
29. Kozarsky K.F., Donahee M.H., Rigotti A., Iqbal S.N., Edelman E.R., Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997, 387:414-417.
30. Wang N., Arai T., Ji Y., Rinninger F., Tall A.R. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J Biol Chem 1998, 273:32920-32926.
31. Ueda Y., Royer L., Gong E., Zhang J., Cooper P.N., Francone O., Rubin E.M. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem 1999, 274:7165-7171.
32. Zhang Y., Da Silva J.R., Reilly M., Billheimer J.T., Rothblat G.H., Rader D.J. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 2005, 115:2870-2874.
33. Fabre A.C., Vantourout P., Champagne E., Terce F., Rolland C., Perret B., Collet X., Barbaras R., Martinez L.O. Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Cell Mol Life Sci 2006, 63:2829-2837.
34. Yamanashi Y., Takada T., Yoshikado T., Shoda J., Suzuki H. NPC2 regulates biliary cholesterol secretion via stimulation of ABCG5/G8-mediated cholesterol transport. Gastroenterology 2011, 140:1664-1674.
35. Garcia-Calvo M., Lisnock J., Bull H.G., Hawes B.E., Burnett D.A., Braun M.P., Crona J.H., Davis H.R., Dean D.C., Detmers P.A., Graziano M.P., Hughes M., Macintyre D.E., Ogawa A., O'Neill K.A., et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005, 102:8132-8137.
36. Laffitte B.A., Repa J.J., Joseph S.B., Wilpitz D.C., Kast H.R., Mangelsdorf D.J., Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A 2001, 98:507-512.
37. Chisholm J.W., Hong J., Mills S.A., Lawn R.M. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 2003, 44:2039-2048.
38. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N., Tran J., Tippin T.K., Wang X., Lusis A.J., Hsueh W.A., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002, 99:7604-7609.
39. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000, 14:2819-2830.
40. Katz A., Udata C., Ott E., Hickey L., Burczynski M.E., Burghart P., Vesterqvist O., Meng X. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 2009, 49:643-649.
41. Peng D., Hiipakka R.A., Dai Q., Guo J., Reardon C.A., Getz G.S., Liao S. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther 2008, 327:332-342.
42. Quinet E.M., Basso M.D., Halpern A.R., Yates D.W., Steffan R.J., Clerin V., Resmini C., Keith J.C., Berrodin T.J., Feingold I., Zhong W., Hartman H.B., Evans M.J., Gardell S.J., DiBlasio-Smith E., et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res 2009, 50:2358-2370.
43. Nakaya K., Tohyama J., Naik S.U., Tanigawa H., MacPhee C., Billheimer J.T., Rader D.J. Peroxisome proliferator-activated receptor-alpha activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Arterioscler Thromb Vasc Biol 2011, 31:1276-1282.
44. Lee F.Y., Lee H., Hubbert M.L., Edwards P.A., Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006, 31:572-580.
45. Rayner K.J., Suarez Y., Davalos A., Parathath S., Fitzgerald M.L., Tamehiro N., Fisher E.A., Moore K.J., Fernandez-Hernando C. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010, 328:1570-1573.
46. Najafi-Shoushtari S.H., Kristo F., Li Y., Shioda T., Cohen D.E., Gerszten R.E., Naar A.M. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010, 328:1566-1569.
47. Marquart T.J., Allen R.M., Ory D.S., Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 2010, 107:12228-12232.
48. Horie T., Ono K., Horiguchi M., Nishi H., Nakamura T., Nagao K., Kinoshita M., Kuwabara Y., Marusawa H., Iwanaga Y., Hasegawa K., Yokode M., Kimura T., Kita T. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A 2010, 107:17321-17326.
49. Rayner K.J., Sheedy F.J., Esau C.C., Hussain F.N., Temel R.E., Parathath S., van Gils J.M., Rayner A.J., Chang A.N., Suarez Y., Fernandez-Hernando C., Fisher E.A., Moore K.J. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011, 121:2921-2931.
50. Kim J.B., Sarraf P., Wright M., Yao K.M., Mueller E., Solanes G., Lowell B.B., Spiegelman B.M. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 1998, 101:1-9.
51. Chen G., Liang G., Ou J., Goldstein J.L., Brown M.S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 2004, 101:11245-11250.
52. Rayner K.J., Esau C.C., Hussain F.N., McDaniel A.L., Marshall S.M., van Gils J.M., Ray T.D., Sheedy F.J., Goedeke L., Liu X., Khatsenko O.G., Kaimal V., Lees C.J., Fernandez-Hernando C., Fisher E.A., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011, 478:404-407.